Wockhardt stock up 10% as Zaynich achieves 96.8% efficacy in Phase III
Wockhardt now intends to file a new drug application (NDA) with the USFDA and seek marketing authorisation application with ...
GlobalData on MSN13h
EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial
The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...
Top 3 Price Prediction Bitcoin, Ethereum, Ripple: BTC, ETH and XRP recovery could be short-lived
Bitcoin (BTC) price hovers around $104,000 on Friday after bouncing off from its 50-day Exponential Moving Average (EMA) of ...
Cryptocurrencies Price Prediction: Bitcoin, Ripple & Ethereum — Asian Wrap 31 January
Bitcoin (BTC) price hovers around $104,000 on Friday after bouncing off from its 50-day Exponential Moving Average (EMA) of ...
Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities
KDEV) today announces that its portfolio company Dilafor has successfully completed regulatory meetings with the U.S. Food and Drug Administration, FDA, and European Health Agencies, regarding the ...
Japanese Yen and Aussie Dollar News: BoJ vs. Fed Rate Path Battle Heats Up
Japan’s retail sales and job data fuel BoJ rate hike bets, pressuring USD/JPY. Fed’s inflation stance also in focus. Will USD ...
Ozempic-Like Drugs May Hold Risks For Surgical Patients, Officials Say
Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.
Here’s Why ImmunityBio, Inc. (IBRX) Will Double in 2025
We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against the other stocks. The Fed’s ...